sponsored
PatientsVille.com Logo

PatientsVille

Clostridium Medical Research Studies

Up-to-date List of Clostridium Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Clostridium Medical Research Studies

Rank Status Study
1 Recruiting A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
Condition: Clostridium Difficile Infection
Interventions: Biological: MK-3415;   Biological: MK-6072;   Biological: MK-3415A;   Biological: Placebo;   Drug: SOC
Outcome Measures: Number of participants with Clostridium difficile infection (CDI) recurrence;   Number of participants with Global Cure;   Number of participants with CDI recurrence in those with clinical cure of the initial CDI episode
2 Not yet recruiting A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
Condition: Clostridium Difficile Associated Disease
Interventions: Biological: Clostridium difficile vaccine;   Biological: Placebo
Outcome Measures: Number of subjects in each treatment group with neutralizing antibody levels greater than or equal to specified thresholds at Day 37.;   Number of subjects reporting local reactions (pain, erythema, and induration) and their severity, as self reported on eDiaries for 7 days following each vaccination.;   Number of subjects reporting systemic reactions (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and their severity, as self reported on eDiaries for 7 days following each vaccination.;   Number of subjects reporting adverse events (AEs) up to 28 days after the last vaccination (Month 2) and serious adverse events (SAEs) throughout the study period.;   Neutralizing antibody levels at various time points after vaccination.;   Number of subjects in each treatment group with 4 and higher fold-rises in neutralizing antibody levels at various time points after vaccination.;   Number of subjects in each treatment group with neutralizing antibody levels greater than or equal to specified thresholds at various time points after vaccination.
3 Not yet recruiting Transplantation of Fecal Microbiota for Clostridium Difficile Infection
Condition: Clostridium Difficile Infection
Intervention: Procedure: Fecal Microbiota transplantation.
Outcome Measures: Clinical remission;   Negative lab test for Clostridium Difficile
4 Recruiting Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients
Conditions: Clostridium Difficile Colonisation;   Impact of Enteral Probiotics on Certain Lab Parameters
Interventions: Dietary Supplement: L. plantarum 299 and L. plantarum 299v (+maltodextrin);   Other: Maltodextrin
Outcome Measures: Differences in emerging cases of Clostridium difficile;   White blood cells;   C Reactive Protein;   Creatinine;   Urea;   Lactate;   Ventilator days;   Length of stay ICU;   Length of Hospital stay;   Survival;   Diarrhea and obstipation
5 Not yet recruiting The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers
Conditions: Clostridium Difficile;   Colitis
Intervention:
Outcome Measures: Development of colitis;   Duration until development of colitis;   Severity of colitis
6 Recruiting Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
Condition: Clostridium Difficile Infection
Intervention:
Outcome Measures: Failure of primary treatment;   Death, CDI recurrence and hospital re-admission with diarrhoea
7 Recruiting Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Condition: Clostridium Difficile Infection
Interventions: Drug: CB-183,315;   Drug: oral vancomycin
Outcome Measures: The proportion of subjects with a clinical outcome of cure;   The clinical response over time based on the length of time it takes for the subjects to fail treatment, recur, die, or become lost to follow-up until Day 40;   The proportion of subjects who sustain a clinical outcome of cure until Day 50
8 Recruiting A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Condition: Clostridium Difficile Infection
Interventions: Drug: CB-183,315;   Drug: oral vancomycin
Outcome Measures: The proportion of subjects with a clinical outcome of cure;   The clinical response over time based on the length of time it takes for the subjects to fail treatment, recur, die, or become lost to follow-up until Day 40;   The proportion of subjects who sustain a clinical outcome of cure until Day 50
9 Recruiting To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis
Condition: Clostridium Difficile
Intervention:
Outcome Measure: To determine the feasibility of a potential interventional study with fidaxomicin
10 Recruiting Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Condition: Clostridium Difficile Infection
Interventions: Biological: C. difficile Toxoid Vaccine;   Biological: Placebo: 0.9% normal saline
Outcome Measures: Number of participants with symptomatic PCR-confirmed primary CDI cases;   The number of participants with symptomatic PCR confirmed primary CDI cases after 3 injections;   The number of participants with symptomatic PCR-confirmed primary CDI cases after 2 injections;   The number of symptomatic PCR-confirmed primary CDI cases after 3 injections as a function of time since enrollment and within 3.0 years or 2.5 years in Stage 1 or Stage 2, respectively, after the third injection;   Serum antibody concentrations against toxins A and B;   Number of Participants Reporting Solicited Injection Site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring Throughout the Trial
11 Recruiting Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
Conditions: Recurrent Clostridium Difficile Infection;   Laboratory Confirmed Clostridium Difficile Infection
Interventions: Drug: Vancomycin;   Biological: Fecal Transplant
Outcome Measure: A Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection.
12 Recruiting Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)
Condition: Infections, Clostridium Difficile
Interventions: Procedure: Blood sampling;   Other: Stool sample collection
Outcome Measures: Immune response to C. difficile as measured in blood samples in all subjects;   Functional immune response to C. difficile as measured in blood samples in all subjects;   Occurrence of CDI recurrence;   Occurrence of the initial CDI episode by severity, in all subjects;   Occurrence of the CDI recurrence by severity, in those subjects who recur;   Occurrence of failure of antibiotic treatment;   Presence of risk factors associated with the initial CDI episode, in all subjects;   Presence of risk factors associated with the CDI recurrence
13 Unknown  Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Conditions: Clostridium Enterocolitis;   Pseudomembranous Colitis
Intervention: Drug: Nitazoxanide
Outcome Measures: Resolution of diarrhea;   Time to resolution of diarrhea;   Recurrence rate;   Number of stools;   Treatment success
14 Recruiting Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Condition: Clostridium Difficile Infection
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Difference in % relapse between Rifaximin and placebo at 12 weeks;   Proportion relapsed, re-hospitalisation and bowel symptoms
15 Recruiting Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea
Conditions: Clostridium Difficile Infection;   Antibiotic Associated Diarrhea
Intervention: Dietary Supplement: Bio-K®
Outcome Measures: To evaluate the incidence of Clostridium Difficile infection;   To evaluate the incidence of antibiotic associated diarrhea
16 Recruiting CHV 11/51 - SERODIFF
Condition: Clostridium Difficile Infection
Interventions: Biological: Serum;   Biological: Stools
Outcome Measures: Serum antibody titers;   Kinetics of antibody;   Clinical evolution;   Antibody titers for each antigen selected;   Risk factors;   Molecular typing of Clostridium difficile strains
17 Recruiting Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin;   Drug: placebo
Outcome Measures: The occurrence of CDAD from start of study treatment up to 30 days post-treatment follow-up in HSCT subjects.;   Occurrence of CDAD from start of study treatment up to 60 days post-treatment
18 Not yet recruiting Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
Conditions: Clostridium Difficile;   Clostridium Difficile Infection
Interventions: Biological: FMT;   Drug: Vancomycin
Outcome Measures: Resolution of diarrhea;   Patient acceptance
19 Not yet recruiting Stool Transplants to Treat Refractory Clostridium Difficile Colitis
Condition: Clostridium Difficile Colitis
Intervention: Biological: fecal microbiota
Outcome Measures: Recurrent colitis due to Clostridium difficile;   Tolerability of oral fecal microbiota transplantation;   Safety of oral fecal microbiota transplantation;   rate of repeat therapy for C. difficile colitis within 6 months of fecal microbiota transplantation.
20 Recruiting Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
Conditions: Crohn's Disease;   Ulcerative Colitis;   Clostridium Difficile;   Inflammatory Bowel Disease
Intervention: Other: Blood and stool sample
Outcome Measures: Colonization;   Incidence

These studies may lead to new treatments and are adding insight into Clostridium etiology and treatment.

A major focus of Clostridium research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Clostridium